Cabot (NYSE:CBT) Posts Earnings Results, Misses Estimates By $0.01 EPS

Cabot (NYSE:CBT - Get Free Report) issued its earnings results on Monday. The specialty chemicals company reported $1.80 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.81 by ($0.01), Briefing.com reports. The business had revenue of $1 billion for the quarter, compared to analysts' expectations of $1.01 billion. Cabot had a return on equity of 26.99% and a net margin of 12.05%. The business's quarterly revenue was up 3.7% on a year-over-year basis. During the same period last year, the company posted $1.65 earnings per share. Cabot updated its FY 2025 guidance to 7.400-7.800 EPS and its FY25 guidance to $7.40-7.80 EPS.

Cabot Stock Down 1.1 %

NYSE:CBT traded down $1.21 on Tuesday, hitting $108.88. 742,048 shares of the company's stock traded hands, compared to its average volume of 337,923. The firm has a 50-day moving average price of $108.30 and a 200-day moving average price of $101.01. The company has a current ratio of 2.22, a quick ratio of 1.45 and a debt-to-equity ratio of 0.72. Cabot has a 1 year low of $66.02 and a 1 year high of $117.14. The company has a market cap of $5.97 billion, a PE ratio of 12.87, a price-to-earnings-growth ratio of 0.91 and a beta of 1.20.

Analyst Ratings Changes

Several equities analysts have weighed in on CBT shares. Mizuho raised their price target on Cabot from $103.00 to $122.00 and gave the stock an "outperform" rating in a research report on Tuesday. UBS Group cut their target price on Cabot from $103.00 to $98.00 and set a "neutral" rating on the stock in a research report on Tuesday, August 6th. Finally, JPMorgan Chase & Co. raised their target price on shares of Cabot from $95.00 to $105.00 and gave the company a "neutral" rating in a research note on Wednesday, August 7th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $105.00.

Insider Buying and Selling

In other news, EVP Hobart Kalkstein sold 5,457 shares of the business's stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $100.58, for a total value of $548,865.06. Following the transaction, the executive vice president now directly owns 61,688 shares of the company's stock, valued at $6,204,579.04. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Cabot news, EVP Hobart Kalkstein sold 5,457 shares of the stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $100.58, for a total value of $548,865.06. Following the transaction, the executive vice president now directly owns 61,688 shares in the company, valued at approximately $6,204,579.04. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Jeff Ji Zhu sold 1,201 shares of the firm's stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $106.19, for a total transaction of $127,534.19. Following the completion of the transaction, the executive vice president now directly owns 96,000 shares in the company, valued at $10,194,240. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 71,939 shares of company stock worth $7,308,812. Insiders own 3.07% of the company's stock.

Cabot Company Profile

Cabot Corporation operates as a specialty chemicals and performance materials company. The company operates through two segments, Reinforcement Materials and Performance Chemicals. It offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.